GOVX (Geovax Labs) Beginning Cash Position: $1.27 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GOVX Geovax Labs Inc GOVX
26 GF Score
Price $0.74
! 1 Warning Sign
View Full Analysis

What is Geovax Labs Beginning Cash Position?

Geovax Labs GOVX +6.11% 26 Beginning Cash Position is $1.27 Mil as of Jun. 2026. GuruFocus rates GOVX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Geovax Labs's Beginning Cash Position for the quarter that ended in Jun. 2026 was $1.27 Mil.

Geovax Labs's quarterly Beginning Cash Position declined from Dec. 2025 ($5.01 Mil) to Mar. 2026 ($3.09 Mil) and declined from Mar. 2026 ($3.09 Mil) to Jun. 2026 ($1.27 Mil).

Geovax Labs's annual Beginning Cash Position declined from Dec. 2023 ($27.61 Mil) to Dec. 2024 ($6.45 Mil) and declined from Dec. 2024 ($6.45 Mil) to Dec. 2025 ($5.51 Mil).

Geovax Labs Beginning Cash Position Related Terms

Geovax Labs Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Geovax Labs's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs Beginning Cash Position Chart

Geovax Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.88 11.42 27.61 6.45 5.51

Geovax Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.44 3.09 5.01 3.09 1.27
GOVX
26GF Score
Geovax Labs Inc GOVX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geovax Labs Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1.27 Mil mean?
Geovax Labs (GOVX) has a Beginning Cash Position of $1.27 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Geovax Labs and its competitors.
Is Geovax Labs' Beginning Cash Position too high?
Geovax Labs' current Beginning Cash Position is $1.27 Mil. Overall, Geovax Labs has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' Beginning Cash Position compare to HCWB and GLMD?
Geovax Labs' Beginning Cash Position of $1.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Geovax Labs and its competitors. Geovax Labs's current Beginning Cash Position is $1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current Beginning Cash Position of $1.27 Mil. The current Beginning Cash Position is $1.27 Mil. Geovax Labs' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Geovax Labs (GOVX), the current Beginning Cash Position is $1.27 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Geovax Labs Business Description

Address 1955 Lake Park Drive, Suite 300, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
26GF Score

Get the complete analysis for GOVX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price